Measuring what matters most to patients begins with understanding how they communicate.
Redenlab CEO Adam Vogel will deliver a keynote at the 19th International Congress on Neuronal Ceroid Lipofuscinosis (NCL).
“Meaningful Measurement: Advancing Speech and Language Endpoints in Neuronal Ceroid Lipofuscinoses”
Date: 28 October – 1 November 2025
Location: Sunshine Coast, Australia
Adam will discuss innovations in speech and language assessment that offer more sensitive, patient-relevant endpoints for NCL clinical trials, helping researchers capture meaningful outcomes that truly reflect patient experience.
If you’re attending the Congress, join the session on the first night or connect with Adam to explore collaboration opportunities.
Learn more about the Congress: https://www.ncl2025.org/program
